Loading company…
UPPTHERA develops targeted protein degradation platforms and therapies.
Founded in 2018 in Incheon, UPPTHERA develops healthcare platforms targeting small cell lung cancer, cardiovascular disease, and multiple myeloma. Its work includes the PROTAC targeted protein degradation platform, a Novel E3 ligase Platform, and UPPGRADER. In May 2022, it raised KRW 28 billion from Meritz Securities, Paratus Investment, and returning investor Albatross Investment to support research on potential SCLC treatments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in